MAPK1 and sarcoma: Finally, in The Cancer Genome Atlas (TCGA), co-amplification of BCL2L13, BID, CRKL and MAPK1 was present in 0.5% of reported samples (Figure S17D, E), being > 2% among sarcomas or lung squamous cell carcinomas.